Clinical Value of Combined Detection of Serum Tumor Markers in Advanced Non-Small Cell Lung Cancer

Abstract

Objectives: To appraise the clinical value of combined detection of serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 724 (CA724), cytokeratin segment 211 (CYFRA211)] in advanced non-small cell lung cancer (NSCLC). Methods: Retrospective analysis of the clinical data of 60 patients with advanced lung cancer (lung cancer subgroup) admitted to the First Peoples Hospital of Lianyungang from January 2021 to September 2022. Other 35 individuals in the same period were selected as the control subgroup; the serum CEA, CA125, CA724 and CYFRA211 levels of all subjects were compared, and the diagnostic value of the single index and combined detection for advanced NSCLC was analyzed by receiver operating characteristic curve (ROC) curve. Results: Compared to the control subgroup, the serum CEA, CA125, CA724 and CYFRA211 levels in the lung cancer subgroup increased. It was confirmed by ROC curve analysis that joint detection was the most effective in diagnosing advanced NSCLC. The area under the curve (AUC) was 0.928, the sensitivity was 78.33%, and the specificity was 91.43%. In each index, CEA and CYFRA211 have similar diagnostic values for NSCLC, which were superior to CA125 and CA724. Conclusions: The concentrations of CEA, CA125, CA724 and CYFRA211 in the serum of patients with advanced NSCLC are increased, which has a certain diagnostic value for the disease, and the combined analysis is more effective.